Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon

Oncologist. 2015 Jan;20(1):88. doi: 10.1634/theoncologist.2014-0273.

Abstract

Shortening of survival after dissemination following adjuvant treatment is not understood well enough and is difficult to search for in public databases because of the lack of specific search terms. We suggest using the acronym ATRESS, for “adjuvant therapy-related shortening of survival,” in future literature concerning this issue.

Publication types

  • Letter
  • Comment

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality*
  • Deoxycytidine / analogs & derivatives*
  • Female
  • Fluorouracil / analogs & derivatives*
  • Humans
  • Taxoids / therapeutic use*

Substances

  • Taxoids
  • Deoxycytidine
  • Fluorouracil